|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Rapid Drugs Of Abuse Screening From Randox
11/24/2009
Crumlin, UK, 24 November 2009: Randox have developed an innovative multi-marker drugs of abuse testing procedure for rapid drug screening programmes. The Drugs of Abuse (DoA) biochips permit the analysis of up to 10 drug classes from a single patient sample providing rapid and accurate testing.
Randox biochip array technology is based on tried and tested ELISA methods. Each 9x9mm biochip comprises up to 25 discrete test regions (DTRs) on which immobilised antibodies specific to each biomarker are contained. In addition, two DTRs are reserved for quality control testing. The Drugs of Abuse biochip arrays demonstrate superior assay performance and also show excellent correlation with GC/MS.
Two Drugs of Abuse biochip arrays are available; DoA array I contains, amphetamine, methamphetamine, barbituates, benzodiazepine 1 & 2, Cannabinoids, cocaine metabolite, methadone, opiates and phencyclidine. DoA array II enables testing for buprenorphine, fentanyl, generic opioids, ketamine, LSD, MDMA, methaqualone, oxycodone 1 & 2 and propoxyphene. As a further feature, creatinine is included on the arrays as a marker of adulteration when testing urine samples. Both biochip arrays are validated for use with urine and whole blood. The use of oral fluid as a sample matrix is validated on DoA array I and currently in development for DoA array II.
Three revolutionary biochip analysers have been developed and can be employed for the Drugs of Abuse arrays. The fully automated Evidence was designed for high throughput laboratories and requires as little as 7µl of urine for all 10 drug classes. This rapid testing platform generates 1088 tests per hour. Once samples are loaded onto the Evidence, the doors are locked and the PC interface is password protected providing chain of custody information. The semi-automated Evidence Investigator for medium size labs and the point of application Evidence MultiStat analyser which generates results in 20 minutes are also available.
The revolutionary Randox Drugs of Abuse biochip array technology will ensure accurate and rapid drug screening guaranteeing confidence in results and ultimately saving valuable time and reducing costs.
About Randox
Randox is an international diagnostics company, headquartered in the UK. Randox develop, manufacture and market clinical diagnostic products worldwide. Core products are: Biochip Array Technology; clinical chemistry analysers and reagents; quality controls and EQA; recombinant proteins and antibodies.
For further information contact:
Randox Laboratories
55 Diamond Road
Crumlin
Co. Antrim BT29 4QY
United Kingdom
|
|
|
|
|
|
|
|
|
|
|
|